 | | Vol. 12.07 – 26 February, 2021 |
| |
|
|
| Researchers identified functional crosstalk between LONP1 and ClpP, two mitochondrial matrix proteases that cooperate to attenuate proteotoxic stress and protect mitochondrial functions for cancer cell survival.
[Oncogenesis] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors investigated the application of the RNA in situ hybridization assay for prostate cancer detection in a cohort of 98 patients suspected of harboring prostate cancer.
[Journal of Urology] |
|
|
|
| Combination treatment with NLG207, a nanoparticle-drug conjugate of camptothecin and inhibitor of HIF-1α, and enzalutamide were evaluated in preclinical prostate cancer models of enzalutamide resistance.
[Molecular Cancer Therapeutics] |
|
|
|
| Investigators sensitized androgen-independent and TNF-related apoptosis inducing ligand (TRAIL)-resistant prostate cancer cells to TRAIL-mediated apoptosis via taxane therapy and examined the mechanism of sensitization.
[Molecular Cancer Therapeutics] |
|
|
|
| Inhibition of glucocorticoid receptor‐mediated glucose transporter 4 suppressed cell proliferation in enzalutamide (Enz)‐resistant prostate cancer cells, which recovered from Enz resistance and cross‐resistance without changes in glucocorticoid receptor expression.
[Cancer Science] |
|
|
|
| Given that both androgen receptor (AR) antagonists and histone deacetylase 6 (HDAC6) inhibitors modulate AR signaling, a novel AR/HDAC6 dual inhibitor was investigated for its anticancer effects in castration-resistant prostate cancer.
[Aging] |
|
|
|
| Researchers investigated a role for opiorphin genes in prostate cancer (PrCa). Databases and PrCa tissue arrays were screened for opiorphin expression.
[Future Oncology] |
|
|
|
|
| Tools for prostate cancer diagnosis have the potential to further improve the identification of men with low-risk disease who can be appropriately managed using active surveillance.
[Nature Reviews Urology] |
|
|
|
| Evaluation of research and clinical trials in gene therapy reveals a concentration of activity in prostate cancer research and practice.
[Nature Reviews Urology] |
|
|
|
|
| ESSA Pharma, Inc. announced that the company has entered into a clinical collaboration and supply agreement with Astellas Pharma, Inc. to evaluate ESSA’s lead product candidate, EPI-7386, in combination with Astellas and Pfizer Inc.’s androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer.
[ESSA Pharma, Inc.] |
|
|
|
| Centre for Probe Development and Commercialization (CPDC) announced that the first patient has been dosed and imaged in a Phase III trial for [18F]Prostate Specific Membrane Antigen (PSMA)-1007. This diagnostic imaging product is a positron-emitting tomography agent that targets PSMA, a protein that is overexpressed in prostate cancer.
[Centre for Probe Development and Commercialization] |
|
|
|
|
| October 27 – 29, 2021
Tokyo, Japan |
|
|
|
|
|
| | Weill Cornell Medicine – New York, New York, United States |
|
|
|
| | CyberCoders – San Diego, California, United States |
|
|
|
| | University of Notre Dame – Notre Dame, Indiana, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | The Francis Crick Institute – London, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
